1.	Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 3 Sponsor: NCI, Other Protocol IDs: CDR0000483683, COG-ACNS0334, ACNS0334, NCT00336024
2.	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000511991, COG-ACNS0332, ACNS0332, NCT00392327
3.	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Phase: Phase III Type: Treatment Status: Active Age: 3 to 21 at diagnosis Sponsor: Other Protocol IDs: SJMB03, SJCRH-SJMB03, NCT00085202
4.	Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 50 and under Sponsor: NCI, Other Protocol IDs: CDR0000687639, COG-AEWS1031, AEWS1031, NCT01231906
5.	A Phase I/II Study of the Photon Radiosurgery System Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
6.	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
7.	Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 30 Sponsor: Other Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
8.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
9.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
10.	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: Pro00018020, NCT01326104
11.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
12.	Antineoplaston Therapy in Treating Children With Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
13.	Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
14.	Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI Protocol IDs: NCI-2011-02605, ACNS0821, U10CA098543, COG-ACNS0821, NCT01217437
15.	Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) Phase: Phase II Type: Treatment Status: Active Age: 3 to 25 Sponsor: Other Protocol IDs: 06-1151, NCT01542736
16.	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 12 to 21 Sponsor: NCI, Other Protocol IDs: PBTC-036, NCI-2013-00482, U01CA081457, NCT01836549
17.	Phase I Study of Photodynamic Therapy With Benzoporphyrin Derivative Monoacid Ring A in Patients With Refractory Brain Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
18.	A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: RADBEV, NCT00756340
19.	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors Phase: Phase I Type: Treatment Status: Active Age: 3 to 22 Sponsor: Pharmaceutical / Industry Protocol IDs: 07-098, NCT00634231
20.	Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 months to 23 years Sponsor: Other Protocol IDs: ACH-CNS-001, NCT00876993
21.	An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma Phase: Phase I Type: Treatment Status: Active Age: Under 18 Sponsor: NINDS Protocol IDs: 090117, 09-N-0117, NCT00880061
22.	Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: 110047, 11-C-0047, NCT01259479
23.	Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: SorIrin1576, NCT01518413
24.	Photodynamic Therapy (PDT) for Brain Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: 163588-1, NCT01682746
25.	Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: TED12689, U1111-1128-5704, NCT01751308